We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Dermatology

Journal Scan / Research · September 23, 2020

Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With Ustekinumab

JAMA Dermatology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Dermatology
Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab
JAMA Dermatol 2020 Sep 09;[EPub Ahead of Print], F Poizeau, E Nowak, S Kerbrat, B Le Nautout, C Droitcourt, MD Drici, E Sbidian, B Guillot, H Bachelez, H Ait-Oufella, A Happe, E Oger, A Dupuy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading